Press Releases September 10, 2026 08:58 AM

Fortrea to Participate in September Investor Conferences

Fortrea announces participation in key September 2026 investor conferences to engage with stakeholders

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
FTRE

Fortrea, a Nasdaq-listed global contract research organization, announced that its top executives will participate in three major healthcare and pharmaceutical investor conferences in September 2026. The events include the Baird Global Healthcare Conference, Deutsche Bank Healthcare Summit, and RBC Pharma Services and Life Science Tools Virtual Conference. These engagements aim to provide investors with insights into Fortrea's clinical development solutions and strategic direction.

Fortrea to Participate in September Investor Conferences
FTRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortrea's CEO, CFO, and SVP of Investor Relations will participate in multiple September investor conferences to engage with stakeholders.
  • The events include prominent healthcare-focused conferences, featuring fireside chats, one-on-one and group meetings.
  • Fortrea provides clinical development solutions spanning Phase I-IV trials across more than 20 therapeutic areas globally.

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Baird 2026 Global Healthcare Conference (NYC)

Date: Tuesday, September 15, 2026
Format: Fireside Chat & 1x1 and Group Meetings
Time: 2:00 -2:30 PM EDT
Webcast: FTRE Baird Webcast

Deutsche Bank 2026 Healthcare Summit (NYC)

Date: Wednesday, September 16, 2026
Format: 1x1 and Group Meetings

RBC Pharma Services and Life Science Tools Virtual Conference

Date: Tuesday, September 22, 2026
Format: 1x1 and Group Meetings

The live webcast and replay of the Baird fireside chat will be accessible through the “Events” section of Fortrea’s Investor Relations website. Investors interested in meeting with management should contact their banking representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]


Risks

  • Investor conferences may not materially impact stock price if new information or guidance is not provided.
  • The company operates in the highly competitive CRO sector, sensitive to biopharmaceutical industry dynamics and drug development risks.
  • Global operational scale across 100 countries exposes Fortrea to geopolitical, regulatory, and operational risks that could impact financial performance.

More from Press Releases

Vishay Intertechnology XClampR® Bidirectional Flat Clamping TVS in DO-218AC Package Deliver Low Clamping Voltage, High Power Density Sep 10, 2026 Nutanix Recognized as a Leader in the Gartner® Distributed Hybrid Infrastructure Magic Quadrant™ Sep 10, 2026 High Roller Technologies to Present at the H.C. Wainwright Global Investment Conference Sep 10, 2026 Old National to Present at the 2026 Barclays Global Financial Services Conference Sep 10, 2026 IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Sep 10, 2026